Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Kura Oncology, Inc. (KURA)

Kura Oncology names Jennifer Fulk as Chief Financial Officer effective September 8, 2026

Neutral Impact 4 of 5 leadership Written later

Kura Oncology appointed Jennifer Fulk as Chief Financial Officer, principal financial officer and principal accounting officer, effective September 8, 2026, replacing Troy E. Wilson and Thomas Doyle in those roles. The filing sets out her $550,000 base salary, an option for 450,000 shares and a performance-based restricted stock unit award covering 173,438 shares, which tie her pay to the company's financial position and development progress.

Key points

  • Jennifer Fulk appointed CFO effective September 8, 2026, replacing Troy E. Wilson in the CFO role and Thomas Doyle as principal accounting officer
  • Annual base salary of $550,000 and discretionary bonus of up to 45% of base salary
  • Option to purchase 450,000 shares, vesting over four years, plus a performance-based RSU award covering 173,438 shares
  • Prior roles include CFO of Soleno Therapeutics (March 2026 to May 2026) and CFO of Talkspace, Inc. (July 2021 to May 2024)

The filing

CompanyKura Oncology, Inc. (KURA)
Form8-K, current report
Filed with the SECSep 8, 2026, 7:05 AM ET
Accession number0001193125-26-384363

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.